| Gregory Scott Kearl, MD | |
|
1509 Wilson Ter, Glendale, CA 91206-4007 | |
| (818) 409-8000 | |
| (818) 546-5632 |
| Full Name | Gregory Scott Kearl |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 1509 Wilson Ter, Glendale, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225052749 | NPI | - | NPPES |
| 00G792270 | Other | CA | BLUE SHIELD |
| 00G792270 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | G79227 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pacific Valley Medical Group | 3577465368 | 96 |
News Archive
UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.
Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.
› Verified 7 days ago
| Entity Name | Pacific Valley Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851312862 PECOS PAC ID: 3577465368 Enrollment ID: O20040122000762 |
News Archive
UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.
Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.
› Verified 7 days ago
| Entity Name | Consultants For Anesthesia & Management Of Pain |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952323909 PECOS PAC ID: 3870539521 Enrollment ID: O20050701000886 |
News Archive
UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.
Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.
› Verified 7 days ago
| Entity Name | Democratic Anesthesiologists, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619343423 PECOS PAC ID: 8224348131 Enrollment ID: O20151105000710 |
News Archive
UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.
Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Scott Kearl, MD 225 S Lake Ave, 535, Pasadena, CA 91101-3005 Ph: (626) 795-6596 | Gregory Scott Kearl, MD 1509 Wilson Ter, Glendale, CA 91206-4007 Ph: (818) 409-8000 |
News Archive
UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.
Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.
› Verified 7 days ago
Mrs. Asmik Akopyan, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1030 S. Glendale Ave., Suite 404, Glendale, CA 91205 Phone: 818-240-9911 Fax: 818-240-9939 | |
Michael S Winston, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 824 N Glendale Ave, Glendale, CA 91206 Phone: 818-500-0523 | |
Dwight E Hiscox, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1509 Wilson Ter, Glendale, CA 91206 Phone: 818-550-0900 Fax: 505-293-1524 | |
Yukiko Ree, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1812 Verdugo Blvd, Glendale, CA 91208 Phone: 818-790-7100 | |
Arthur Victor Liu, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1509 Wilson Ter, Glendale, CA 91206 Phone: 818-409-8000 Fax: 818-546-5632 | |
Varner Edward Dudley Iii, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1509 Wilson Ter, Glendale, CA 91206 Phone: 818-409-8000 Fax: 818-546-5632 | |
Ivan Hronek, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1420 S Central Ave, Glendale, CA 91204 Phone: 818-502-1900 Fax: 818-502-4738 |